Career history of Tamara Byk
Former positions of Tamara Byk
| Companies | Position | Start | End |
|---|---|---|---|
| EVOGENE LTD. | Chief Tech/Sci/R&D Officer | 2006-07-31 | 2009-09-30 |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 2001-12-31 | 2003-12-31 |
| SOLEGREEN | Corporate Officer/Principal | - | - |
Training of Tamara Byk
| The Hebrew University of Jerusalem | Doctorate Degree |
Statistics
International
| Israel | 4 |
| United States | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
| Utilities | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| EVOGENE LTD. | Health Technology |
| SOLEGREEN | Utilities |
| Private companies | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Stock Market
- Insiders
- Tamara Byk
- Experience
